Alogliptin Switch Guidance-Prescribing Quality Incentive Scheme 2016/17 RationaleAlogliptin Switch Guidance • April 17th, 2018
Alogliptin (Vipidia®) is the first line formulary gliptin for use in the management of type 2 diabetes in line with NICE guidance. Alogliptin is as effective as other gliptins, and costs 16 to 20% less than other agents in this class.
